ANI Pharmaceuticals Inc
NASDAQ:ANIP

Watchlist Manager
ANI Pharmaceuticals Inc Logo
ANI Pharmaceuticals Inc
NASDAQ:ANIP
Watchlist
Price: 57.86 USD -1.33%
Market Cap: 1.2B USD
Have any thoughts about
ANI Pharmaceuticals Inc?
Write Note

ANI Pharmaceuticals Inc
Total Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

ANI Pharmaceuticals Inc
Total Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
ANI Pharmaceuticals Inc
NASDAQ:ANIP
Total Current Liabilities
$189.9m
CAGR 3-Years
31%
CAGR 5-Years
2%
CAGR 10-Years
37%
Johnson & Johnson
NYSE:JNJ
Total Current Liabilities
$51.8B
CAGR 3-Years
5%
CAGR 5-Years
8%
CAGR 10-Years
8%
Bristol-Myers Squibb Co
NYSE:BMY
Total Current Liabilities
$22.6B
CAGR 3-Years
2%
CAGR 5-Years
17%
CAGR 10-Years
11%
Pfizer Inc
NYSE:PFE
Total Current Liabilities
$43.8B
CAGR 3-Years
2%
CAGR 5-Years
3%
CAGR 10-Years
8%
Merck & Co Inc
NYSE:MRK
Total Current Liabilities
$29.6B
CAGR 3-Years
8%
CAGR 5-Years
7%
CAGR 10-Years
1%
Eli Lilly and Co
NYSE:LLY
Total Current Liabilities
$24.7B
CAGR 3-Years
22%
CAGR 5-Years
18%
CAGR 10-Years
13%
No Stocks Found

ANI Pharmaceuticals Inc
Glance View

Market Cap
1.2B USD
Industry
Pharmaceuticals

ANI Pharmaceuticals, Inc. is a pharmaceutical company, which engages in developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. The company is headquartered in Baudette, Minnesota and currently employs 601 full-time employees. The company went IPO on 2000-05-04. The firm is focused on developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. The firm focuses on areas, including controlled substances, oncology products (anti-cancer), hormones and steroids, and complex formulations. The Company’s products include both branded and generic pharmaceuticals. Its generic products include Aspirin and Extended Release Dipyridamole, Bretylium Tosylate Injection USP, cholestyramine, Etodolac, Fluvoxamine, Indapamide, Nilutamide, Vancomycin and more. Its branded products include Arimidex (anastrozole) tablets, Atacand HCT Tablets, Atacand (candesartan cilexetil) Tablets, Casodex, Cortenema, Cortrophin gel, Cortrophin-Zinc, Inderal LA, Inderal XL, InnoPran XL, Lithobid, Reglan and Vancocin. The company operates across three pharmaceutical manufacturing facilities, of which two are located in Baudette, Minnesota and one is located in Oakville, Ontario.

ANIP Intrinsic Value
96.33 USD
Undervaluation 40%
Intrinsic Value
Price

See Also

What is ANI Pharmaceuticals Inc's Total Current Liabilities?
Total Current Liabilities
189.9m USD

Based on the financial report for Sep 30, 2024, ANI Pharmaceuticals Inc's Total Current Liabilities amounts to 189.9m USD.

What is ANI Pharmaceuticals Inc's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
37%

Over the last year, the Total Current Liabilities growth was 41%. The average annual Total Current Liabilities growth rates for ANI Pharmaceuticals Inc have been 31% over the past three years , 2% over the past five years , and 37% over the past ten years .

Back to Top